Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on the development of the drug in ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Having lupus may increase your risk of food allergies. And certain foods may trigger lupus flares. Learn more.